Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247843 | 1.00 | KDM4E (0.37) | KDM4EGRIK1PTGS1AKR1C3 | |
| SCHEMBL28154184 | 0.82 | KDM4E (0.32) | KDM4E | |
| SCHEMBL6726481 | 0.82 | KDM4E (0.32) | KDM4E | |
| SCHEMBL14675185 | 0.79 | PTGS1 (0.31) | GRIK1PTGS1AKR1C3 | |
| SCHEMBL3621930 | 0.79 | PTGS1 (0.31) | GRIK1PTGS1AKR1C3 | |
| SCHEMBL1469906 | 0.79 | PTGS1 (0.31) | GRIK1PTGS1AKR1C3 | |
| SCHEMBL28321184 | 0.78 | — | — | |
| SCHEMBL1924255 | 0.77 | PTGS1 (0.30) | PTGS1AKR1C3 | |
| SCHEMBL1142234 | 0.77 | HMGCR (0.32) | PTGS1AKR1C3 | |
| SCHEMBL30828310 | 0.77 | HMGCR (0.42) | KDM4EPTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541017-B2 | Fortified micronutrient salt formulations | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-01-03 | — | — | US | claimed |
| US-7819914-B2 | Adhesion promoting primer for coated surfaces | CORDIS CORPORATION (US) | 2010-10-26 | — | — | US | claimed |
| US-20100152841-A1 | ADHESION PROMOTING PRIMER FOR COATED SURFACES | CORDIS US CORP | 2010-06-17 | — | — | US | claimed |
| EP-1521574-B1 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING A LIPOPHILIC ACTIVE PRINCIPLE AND PREPARATION METHOD THEREOF | CLL PHARMA (FR) | 2007-03-07 | — | — | EP | claimed |
| WO-2006110540-A2 | ANTIMICROBIAL POLYMER COATINGS AND A METHOD PRODUCING THEM VIA CHEMICAL VAPOUR DEPOSITION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-10-19 | — | — | WO | claimed |
| US-20060228966-A1 | Chemical vapor deposition of antimicrobial polymer coatings | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-10-12 | — | — | US | claimed |
| EP-1521574-A1 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING A LIPOPHILIC ACTIVE PRINCIPLE AND PREPARATION METHOD THEREOF | CLL PHARMA (FR) | 2005-04-13 | — | — | EP | claimed |
| WO-2004000279-A1 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING A LIPOPHILIC ACTIVE PRINCIPLE AND PREPARATION METHOD THEREOF | CLL PHARMA (FR) | 2003-12-31 | — | — | WO | claimed |
| EP-3891229-B1 | PROCESS FOR PREPARING A SURFACE WITH BACTERIOSTATIC ACTIVITY AND SURFACE THUS PREPARED | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-03-27 | — | — | EP | disclosed |
| EP-3292866-B1 | ACETAMINOPHEN / IBUPROFEN COMBINATIONS | JOHNSON & JOHNSON CONSUMER INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20220073758-A1 | PROCESS FOR PREPARING A SURFACE WITH BACTERIOSTATIC ACTIVITY AND SURFACE THUS PREPARED | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2022-03-10 | — | — | US | disclosed |
| EP-3891229-A1 | PROCESS FOR PREPARING A SURFACE WITH BACTERIOSTATIC ACTIVITY AND SURFACE THUS PREPARED | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115434-A1 | PROCESS FOR PREPARING A SURFACE WITH BACTERIOSTATIC ACTIVITY AND SURFACE THUS PREPARED | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-06-11 | — | — | WO | disclosed |
| US-10363221-B2 | Manufacturing solid pharmaceutical dosage forms with visible micro- and nanostructured surfaces and micro- and nanostructured pharmaceutical dosage form | I-PROPERTY HOLDING CORP. (US) | 2019-07-30 | — | — | US | disclosed |
| US-5096489-A | 2-hydroxyphenyl-s-triazines | CIBA-GEIGY CORPORATION (US) | 1992-03-17 | — | — | US | disclosed |
| US-5073381-A | Sustained drug release | UNIVERSITY OF AKRON (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0460385-A2 | Polymeric biocidal agents | H.B. FULLER LICENSING & FINANCING, INC. (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0456093-A2 | Biguanide derivatives and biocidal compositions containing them | H.B. FULLER LICENSING & FINANCING, INC. (US) | 1991-11-13 | — | — | EP | disclosed |
| US-4942204-A | METHACRYLOYL ENDCAPPED POLYISOBUTYLENE COPOLYMERIZED WITH DIMETHYLAMINOETHYL METHACRYLATE | THE UNIVERSITY OF AKRON (US) | 1990-07-17 | — | — | US | disclosed |
| US-4908381-A | Tetrahydropyran containing unsaturated ester or amide derivative | ECOLAB INC. (US) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073758-A1 | PROCESS FOR PREPARING A SURFACE WITH BACTERIOSTATIC ACTIVITY AND SURFACE THUS PREPARED | DRD1, DRD2, DRD4 | KDM4E 4194/4885GRIK1 2299/4885PTGS1 959/4885 |
| US-10363221-B2 | Manufacturing solid pharmaceutical dosage forms with visible micro- and nanostructured surfaces and micro- and nanostructured pharmaceutical dosage form | MITF, MYOF, RAB5IF | KDM4E 3851/4885GRIK1 4526/4885PTGS1 2476/4885 |
| US-11541017-B2 | Fortified micronutrient salt formulations | SLC5A6, SI, SLC19A1 | KDM4E 1929/4885GRIK1 3116/4885PTGS1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.